tiprankstipranks
Advertisement
Advertisement

ANRO Stock Latest News

Alto Neuroscience price target raised to $55 from $50 at H.C. Wainwright
The FlyAlto Neuroscience price target raised to $55 from $50 at H.C. Wainwright
4h ago
ANRO
Alto Neuroscience reports Q EPS (65c), consensus (77c)
PremiumThe Fly
Alto Neuroscience reports Q EPS (65c), consensus (77c)
11h ago
ANRO
Alto Neuroscience price target raised to $37 from $28 at BTIG
PremiumThe Fly
Alto Neuroscience price target raised to $37 from $28 at BTIG
11h ago
ANRO
Alto Neuroscience price target raised to $37 from $33 at BofA
PremiumThe Fly
Alto Neuroscience price target raised to $37 from $33 at BofA
1d ago
ANRO
Analyst Lifts ALTO-207 Price Target to $37 on Strong TRD Profile and Expanded Monotherapy Strategy, Reiterates Buy
PremiumRatings
Analyst Lifts ALTO-207 Price Target to $37 on Strong TRD Profile and Expanded Monotherapy Strategy, Reiterates Buy
4d ago
ANRO
Alto Neuroscience Raises Capital to Advance ALTO-207
PremiumCompany AnnouncementsAlto Neuroscience Raises Capital to Advance ALTO-207
1M ago
8K
ANRO
Alto Neuroscience Highlights Strong Cash, Expands ALTO-207 Trials
Premium
Company Announcements
Alto Neuroscience Highlights Strong Cash, Expands ALTO-207 Trials
1M ago
8K
ANRO
Alto Neuroscience prices 3.78M shares at $26.48 in registered direct offering
Premium
The Fly
Alto Neuroscience prices 3.78M shares at $26.48 in registered direct offering
1M ago
ANRO
Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol
PremiumThe Fly
Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol
2M ago
ANRO
Alto Neuroscience Appoints Andrew Miller to Board
PremiumCompany Announcements
Alto Neuroscience Appoints Andrew Miller to Board
3M ago
8K
ANRO
Alto Neuroscience appoints Miller to Board of Directors
PremiumThe Fly
Alto Neuroscience appoints Miller to Board of Directors
3M ago
ANRO
Alto Neuroscience Buy Rating Reiterated as Analyst Highlights De-Risked Pipeline, Strong Cash Runway and Maintains $50 Price Target
PremiumRatings
Alto Neuroscience Buy Rating Reiterated as Analyst Highlights De-Risked Pipeline, Strong Cash Runway and Maintains $50 Price Target
3M ago
ANRO
Alto Neuroscience price target lowered to $33 from $35 at BofA
PremiumThe FlyAlto Neuroscience price target lowered to $33 from $35 at BofA
3M ago
ANRO
Alto Neuroscience price target lowered to $36 from $38 at Baird
Premium
The Fly
Alto Neuroscience price target lowered to $36 from $38 at Baird
3M ago
ANRO
Alto Neuroscience price target raised to $24 from $21 at Wedbush
Premium
The Fly
Alto Neuroscience price target raised to $24 from $21 at Wedbush
3M ago
ANRO
Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained
PremiumRatings
Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained
3M ago
ANRO
Ritu Baral Reiterates Buy on Alto Neuroscience, Citing Pivotal ALTO-207 Phase 2b Trial in TRD and Strong Cash Runway Through 2029
PremiumRatings
Ritu Baral Reiterates Buy on Alto Neuroscience, Citing Pivotal ALTO-207 Phase 2b Trial in TRD and Strong Cash Runway Through 2029
3M ago
ANRO
Alto Neuroscience Shareholders Shape Governance and Equity Plans
PremiumCompany Announcements
Alto Neuroscience Shareholders Shape Governance and Equity Plans
3M ago
8K
ANRO
Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year
PremiumThe Fly
Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year
3M ago
ANRO
Alto Neuroscience initiated with a Buy at BofA
PremiumThe FlyAlto Neuroscience initiated with a Buy at BofA
3M ago
ANRO
Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD
Premium
The Fly
Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD
4M ago
ANRO
Alto Neuroscience participates in a conference call with H. C. Wainwright
Premium
The Fly
Alto Neuroscience participates in a conference call with H. C. Wainwright
4M ago
ANRO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >